Evolus, Inc. (NASDAQ:EOLS) Insider Sells $370,007.04 in Stock

Evolus, Inc. (NASDAQ:EOLS) insider Rui Avelar sold 27,904 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $370,007.04. Following the transaction, the insider now directly owns 362,467 shares in the company, valued at approximately $4,806,312.42. This represents a 7.15 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Rui Avelar also recently made the following trade(s):

• On Monday, December 23rd, Rui Avelar sold 2,252 shares of Evolus stock. The shares were sold at an average price of $10.85, for a total value of $24,434.20.

Evolus Price Performance

EOLS opened at $13.03 on Friday. The business has a fifty day moving average of $13.42 and a 200 day moving average of $13.88. Evolus, Inc. has a 52-week low of $9.25 and a 52-week high of $17.82. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The stock has a market cap of $828.54 million, a P/E ratio of -14.32 and a beta of 1.28.

Hedge Funds Weigh In On Evolus

A number of large investors have recently bought and sold shares of the business. Jefferies Financial Group Inc. purchased a new position in Evolus during the 4th quarter valued at $753,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Evolus by 6.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 115,052 shares of the company’s stock worth $1,270,000 after buying an additional 6,821 shares during the period. Zimmer Partners LP lifted its holdings in shares of Evolus by 66.6% in the 4th quarter. Zimmer Partners LP now owns 416,500 shares of the company’s stock worth $4,598,000 after buying an additional 166,500 shares during the period. Tang Capital Management LLC lifted its holdings in shares of Evolus by 3.1% in the 4th quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company’s stock worth $55,171,000 after buying an additional 150,000 shares during the period. Finally, Rafferty Asset Management LLC purchased a new stake in shares of Evolus in the 4th quarter worth $115,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Barclays boosted their target price on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. HC Wainwright reissued a “buy” rating and set a $27.00 target price on shares of Evolus in a research report on Wednesday, March 5th. Finally, Needham & Company LLC reissued a “buy” rating and set a $22.00 target price on shares of Evolus in a research report on Wednesday, March 5th.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.